Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1–Diagnosed Adults

Figures & data

Table 1 Sociodemographic and Disease Characteristics for Respondents at Baseline and Follow-Up

	Baseline	Follow-Up
	(n=100)	(n=43)
Sociodemographics
Gender, n (%)
Male	69 (69.0)	28 (65.0)
Age, mean ± SD, years	38.8 ± 10.8	39.5 ± 11.5
Age groups, n (%), years
18–30	26 (26.0)	10 (23.2)
31–40	35 (35.0)	15 (35.9)
41–50	21 (21.0)	9 (20.9)
51–60	13 (13.0)	5 (11.6)
>60	5 (5.0)	4 (9.3)
Race
Caucasian	48 (48.0)	14 (32.6)
African American	35 (35.0)	24 (55.8)
Asian	11 (11.0)	4 (9.3)
American Indian or Alaska Native	5 (5.0)	0
Native Hawaiian or Other Pacific Islander	1 (1.0)	1 (2.3)
Prefer not to say	1 (1.0)	0
Ethnicity
Not Hispanic nor Latino nor Spanish Origin	84 (84.0)	39 (90.7)
Patient with comorbidities, n (%)	22 (22.0)	12 (27.9)
Disease characteristics
Age at HIV-1 diagnosis, mean ± SD, years	30.6 ± 8.8	29.9 ± 7.0
n (%), years
At birth	1 (1.0)	0
≤17	3 (3.0)	2 (4.6)
18–30	50 (50.0)	21 (48.8)
31–40	33 (33.0)	18 (41.9)
41–50	9 (9.0)	2 (4.6)
51–60	4 (4.0)	0
≥61	0	0
Time since HIV-1 diagnosis, mean ± SD, years	8.2 ± 8.8	9.6 ± 9.0
n (%), years
≤5	58 (58.0)	19 (44.2)
6–10	15 (15.0)	10 (23.2)
11–15	10 (10.0)	6 (13.9)
16–20	4 (4.0)	0
21–25	7 (7.0)	5 (11.6)
≥25	6 (6.0)	3 (7.0)
HIV-1 stage^a
1	3 (3.0)	1 (2.3)
2	72 (72.0)	31 (72.1)
3	18 (18.0)	8 (18.6)
Do not know	7 (7.0)	3 (7.0)
Viral suppression^b
Yes	73 (73.0)	31 (72.1)
No	15 (15.0)	7 (16.3)
Do not know	12 (12.0)	5 (11.6)
Patient who took another ART before DRV/c/FTC/TAF, n (%)	76 (76.0)	34 (79.1)
Number of past ARTs before DRV/c/FTC/TAF
n (%)
0	24 (24.0)	9 (20.9)
1	34 (34.0)	12 (27.9)
2	14 (14.0)	8 (18.6)
3	9 (9.0)	4 (9.3)
≥4	19 (19.0)	10 (23.2)
Time since DRV/c/FTC/TAF start, mean ± SD, years	11.2 ± 6.2	11.2 ± 6.6
Months
0–3	9 (9.0)	5 (11.6)
4–6	20 (20.0)	8 (18.6)
7–9	14 (14.0)	4 (9.3)
10–12	12 (12.0)	6 (13.9)
≥12	45 (45.0)	20 (46.5)

Note: ^aDefined as acute HIV-1 infection (stage 1), chronic HIV-1 infection (stage 2), and terminal phase of the disease (AIDS, stage 3). ^bOf the 88% of patients who knew they were virally suppressed, 70% had a viral load test within the last 6 months.

Abbreviations: SD, standard deviation; HIV-1, human immunodeficiency virus type 1; ART, antiretroviral therapy; DRV/c/FTC/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; AIDS, acquired immunodeficiency syndrome.

Figure 1 Study population flowchart.

Abbreviations: DRV/c/FTC/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; ART, antiretroviral therapy; HIV, human immunodeficiency virus.

Table 2 HIVTSQs Total and Individual Item Scores at Baseline and Follow-Up

Individual Items^a	HIVTSQs			p-value^c
	Baseline	Follow-Up
	Baseline (n=100)	Baseline^b (n=43)	Follow-Up (n=43)
General satisfaction/clinical subscale (sum)	25.3	25.7	25.0	0.2
Current treatment^d	5.1	5.2	5.2	1.0
Control^e	5.0	5.2	5.2	0.9
Side effects^d	4.7	4.7	4.5	0.5
Recommend to others^f	5.2	5.4	5.1	0.08
Continue^d	5.2	5.3	5.0	0.1
Lifestyle/ease subscale (sum)	25.0	25.7	25.3	0.5
Demands^d	5.0	5.1	5.0	0.8
Convenience^g	5.0	5.1	4.9	0.4
Flexibility^h	4.9	4.9	4.8	0.7
Understanding^d	5.2	5.3	5.3	1.0
Lifestyle^d	5.0	5.3	5.2	0.7
Total score (maximum 60)	50.2	51.4	50.2	0.3

Notes: ^aHIVTSQs individual item names abbreviated as in prior studies.¹³ bIncludes only those respondents who completed questionnaires at both baseline and follow-up. ^cp-value between baseline and follow-up data for the 43 respondents who answered both questionnaires. ^d6=very satisfied, 0=very dissatisfied. ^e6=very well-controlled, 0=very poorly controlled. ^f6=yes, I would definitely recommend the treatment, 0= no, I would definitely not recommend the treatment. ^g6=very convenient, 0=very inconvenient. ^h6=very flexible, 0=very inflexible.

Abbreviation: HIVTSQs, HIV Treatment Satisfaction Questionnaire status version.

Figure 2 Percentage of respondents satisfied (HIVTSQs) at baseline.^a

Note: ^aHIVTSQs individual item names abbreviated as in prior studies.¹³.

Abbreviation: HIVTSQs, HIV Treatment Satisfaction Questionnaire status version.

Figure 3 Percentage of respondents satisfied (HIVTSQs) among those who completed questionnaires at both baseline and follow-up.^a

Note: ^aHIVTSQs individual item names abbreviated as in prior studies.¹³.

Abbreviation: HIVTSQs, HIV Treatment Satisfaction Questionnaire status version.

Figure 4 Percentage of respondents with overall symptoms (grades 1–4) or bothersome symptoms (grades 3–4) on HIV-SDM at baseline.^a

Note: ^aHIV-SDM item names abbreviated as in prior studies.¹⁴.

Abbreviation: HIV-SDM, HIV Symptom Distress Module.

Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res. 2001;10(6):517–531. doi:10.1023/A:1013050904635

 PubMed Web of Science ®Google Scholar

Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77–90. doi:10.1016/S0895-4356(01)00449-8

 PubMed Web of Science ®Google Scholar